Zobrazeno 1 - 10
of 99
pro vyhledávání: '"RR, risk ratio"'
Autor:
John C. O’Horo, M. Rizwan Sohail, Zachary A Yetmar, Andrew D. Badley, Douglas W. Challener, Imad M. Tleyjeh, James R. Cerhan
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 2, Pp 442-446 (2021)
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Objective To determine the association between chronic statin use and mortality in patients hospitalized with coronavirus disease 2019 (COVID-19). Patients and Methods We identified a retrospective cohort of patients requiring admission at the Mayo C
Publikováno v:
Indian Pacing and Electrophysiology Journal, Vol 21, Iss 1, Pp 36-43 (2021)
Indian Pacing and Electrophysiology Journal
Indian Pacing and Electrophysiology Journal
Background Among many drugs that hold potential in COVID-19 pandemic, chloroquine (CQ), and its derivative hydroxychloroquine (HCQ) have generated unusual interest. With increasing usage, there has been growing concern about the prolongation of QTc i
Autor:
Antonino Giarratano, Pasquale Iozzo, Andrea Cortegiani, Sharon Einav, Mariachiara Ippolito, Giulia Ingoglia
Publikováno v:
Journal of Critical Care
Purpose To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans. Materials and methods MEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched
Autor:
Stephen D. Wiviott, Michael A. Blazing, Andrew M. Tershakovec, Robert M. Califf, Eugene Braunwald, Charles S. Fuchs, Jeong-Gun Park, Robert P. Giugliano, Christopher P. Cannon, Wolfram Goessling, Baris Gencer, Thomas Musliner
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 3, Pp 385-396 (2020)
JACC: CardioOncology
JACC: CardioOncology
Background An increased risk of malignancy was reported with simvastatin/ezetimibe in 1,873 patients in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial. Objectives The purpose of this study was to clarify this unexpected finding in a la
Autor:
Caleb Scheidel, Madeline Schaeffer, Zeyad Sako, Fatima Fayyaz, Richard A. Shellenberger, Mohammed Nabhan, Karine Tawagi
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 4, Iss 4, Pp 373-383 (2020)
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 4, Iss 4, Pp 373-383 (2020)
We performed a systematic review and meta-analysis to examine the relationship between the type of biopsy technique employed in the diagnosis of cutaneous melanoma and 4 clinically important outcomes: melanoma-specific mortality, all-cause mortality,
Publikováno v:
JACC: CardioOncology
JACC. CardioOncology, Vol 2, Iss 3, Pp 428-440 (2020)
JACC. CardioOncology, Vol 2, Iss 3, Pp 428-440 (2020)
Background Many patients with cancer have a hypercoagulable state and an increased risk of developing venous thromboembolism (VTE), arterial occlusion, and pulmonary emboli. Patients with cancer may also have an increased risk of bleeding with antico
Autor:
Michele Miraglia del Giudice, Cristiana Indolfi, Giulio Dinardo, Fabio Decimo, Alberto Decimo, Angela Klain
Publikováno v:
PharmaNutrition. 22:100319
Background: vitamin D influences the immune system and the inflammatory response. It is known that vitamin D supplementation reduces the risk of acute respiratory tract infection. In the last two years, many researchers have investigated vitamin D's
Publikováno v:
Annals of Medicine and Surgery
Background Increasing evidence shows that patients with Metabolic Syndrome (MetS) are at risk for adverse outcome after abdominal surgery. The aim of this study was to investigate the impact of MetS and preoperative hyperglycemia, as an individual co
Publikováno v:
Heart & Lung
Background COVID-19 causes fatal cardiac damages. Despite many overwhelming meta-analysis related to cardiac complications following COVID-19 disease, no umbrella meta-analysis study has been conducted. Objectives We aimed to report the summarized po
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 12, Pp 101238-(2021)
Translational Oncology, Vol 14, Iss 12, Pp 101238-(2021)
Highlights • Sorafenib in combination with TACE can prolong survival in patients with hepatocellular carcinoma. • Compared with TACE + placebo / alone, the combination of TACE and sorafenib can significantly improve the efficacy and safety of hep